New drug tested to tame debilitating itch in kids with rare liver disease
NCT ID NCT05543187
Summary
This study tested an investigational drug called TAK-625 in Japanese children with a rare, inherited liver disease called PFIC. The main goal was to see if the drug could reduce the severe, life-altering itching caused by the disease and lower harmful bile acid levels in the blood. Five participants received the drug for up to 34 months while researchers monitored their symptoms and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Kyushu University Hospital
Fukuoka, Japan
-
Osaka University Hospital
Suita, Osaka, Japan
-
Saitama Prefectural Children's Medical Center
Saitama, Japan
-
Tsuyama Chuo Hospital
Tsuyama, Okayama-ken, Japan
-
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
-
Yokohamashi Tobu Hospital
Yokohama, Kanagawa, Japan
Conditions
Explore the condition pages connected to this study.